XLO

Xilio Development Inc

XLO, USA

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

https://xiliotx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XLO
stock
XLO

Xilio Therapeutics announces pricing of $50 million public offering MSN

Read more →
XLO
stock
XLO

Can Xilio Therapeutics Stock Recover If Markets Fall? Trefis

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$2

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-12.12

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

201.20 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-12.18 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-91.76 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 31.08% of the total shares of Xilio Development Inc

2.

Merck & Co Inc

(2.8629%)

since

2025/06/30

3.

Takeda Pharmaceutical Co Ltd

(2.8462%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(2.7868%)

since

2025/06/30

5.

Ghisallo Capital Management LLC

(2.572%)

since

2025/06/30

6.

Vanguard Group Inc

(2.2209%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(1.3964%)

since

2025/07/31

8.

AJU IB Investment Co Ltd

(1.2884%)

since

2025/06/30

9.

FMR Inc

(0.9875%)

since

2025/06/30

10.

Geode Capital Management, LLC

(0.7132%)

since

2025/06/30

11.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5728%)

since

2025/07/31

13.

UBS Group AG

(0.463%)

since

2025/06/30

14.

Squarepoint Ops LLC

(0.4543%)

since

2025/06/30

15.

Balyasny Asset Management LLC

(0.3837%)

since

2025/06/30

16.

Fidelity Extended Market Index

(0.3594%)

since

2025/07/31

17.

Renaissance Technologies Corp

(0.3168%)

since

2025/06/30

18.

Honkamp Krueger Financial Services Inc

(0.2746%)

since

2025/06/30

19.

Two Sigma Investments LLC

(0.1506%)

since

2025/06/30

20.

Northern Trust Corp

(0.1285%)

since

2025/06/30

21.

Fidelity Total Market Index

(0.1227%)

since

2025/07/31

22.

Bridgeway Capital Management, LLC

(0.1082%)

since

2025/06/30

23.

Bridgeway Ultra-Small Company Market

(0.1082%)

since

2025/06/30

24.

Fidelity Series Total Market Index

(0.0966%)

since

2025/07/31

25.

State Street Corp

(0.0837%)

since

2025/06/30

26.

XTX Topco Ltd

(0.067%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - NL

(0.067%)

since

2025/06/30

28.

Spartan Extended Market Index Pool F

(0.0664%)

since

2025/07/31

29.

NT Ext Equity Mkt Idx Fd - L

(0.0598%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.0598%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.052%)

since

2025/06/30

32.

Spartan Total Market Index Pool G

(0.0404%)

since

2025/07/31

33.

Fidelity Nasdaq Composite Index

(0.0276%)

since

2025/07/31

34.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0169%)

since

2025/06/30

35.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0142%)

since

2024/12/31

36.

State St US Extended Mkt Indx NL Cl C

(0.0062%)

since

2025/08/31

37.

Vanguard U.S. Eq Idx £ Acc

(0.0057%)

since

2025/07/31

38.

SSgA U.S. Total Market Index Strategy

(0.0026%)

since

2025/03/31

39.

Northern Trust Wilshire 5000

(0.0017%)

since

2025/06/30

40.

State St US Ttl Mkt Indx NL Cl A

(0.0017%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1

Latest Release

Date

2025-09-30

EPS Actual

-0.11

EPS Estimate

-0.05

EPS Difference

-0.06

Surprise Percent

-120%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.